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ABSTRACT 
Background: Published experience of treating chronic hepatitis D patients 
with pegylated interferon (PEG-IFN) alpha is limited. The aim of this study 
was to determine the efficacy of 48 weeks treatment with PEG-IFN in naïve 
patients outside the clinical trial setting in the real world. 
Methods: Patients with chronic hepatitis D were treated with PEG-IFN. The 
primary end points were sustained clearance of HDV RNA and normal 
alanine aminotransferase (ALT) at 24 weeks post-treatment. 
Results: Patients treated with PEG-IFN were 104; male 91, mean age 30.1 ± 
10.0 years (range 15-55). Cirrhosis was present in 41 patients. With an 
intention to treat analysis, end of treatment virological response (ETR) was 
achieved in 44 (42.3%), normalization of ALT in 38 (35%) and a combined 
response in 23 (22.1%) patients. Sustained virological response (SVR) at 24 
weeks post-treatment was seen in 24 (23.1%) patients each for the 
virological and biochemical responses and in 13 (12.5%) as combined 
response. Both ETR and SVR were associated with a negative HDV RNA at 
24 weeks of treatment (p= 0.001 and 0.000). Detectable HDV RNA at this 
point had a positive predictive value of 0.95 (0.85-0.99) for a detectable RNA 
at six months post treatment. End of treatment biological response i.e. 
normal ALT at the end of treatment was also a predictor of ETR and SVR (p 
= 0.004 and 0.041). 
Conclusions: Treatment with PEG-IFN for hepatitis D is of limited efficacy. 
Detectable HDV RNA at 24 weeks of treatment is a predictor for a failed 
SVR. 
Accepted 19 December 2013, published online 14 January 2014 
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Abbreviations: 
HDV, hepatitis D virus; PEG-IFN, pegylated interferon alpha; ALT, alanine aminotransferase; 
RNA, ribonucleic acid; ETR, end of treatment virological response; SVR, sustained virological 
response; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; PCR, polymerase chain reaction; HBeAg, hepatitis Be antigen 
INTRODUCTION 
HDV is a defective RNA agent needing the presence of HBV for its own replication [1]. Persistent 
HDV replication leads to cirrhosis and hepatocellular carcinoma at annual rates of 4% and 2.8% 
respectively [2]. This figure underscores the need to treat this infection. Unfortunately, there is no 
effective antiviral therapy available for the treatment of hepatitis D. The only established therapy 
for chronic delta hepatitis is interferon alpha, standard or pegylated, which has to be administered 
for at least 48 weeks [3]. 
A recent Cochrane review showed that therapy with standard interferons may result in an 
end of treatment virological and biochemical response in one third of patients but sustained 
virological response, judged by loss of HDV RNA from serum at six months, was seen in only 
17.4% of patients. Histological improvement was seen in one-quarter of the patients [4]. 
The experience of using pegylated interferon (PEG-IFN) alpha in delta hepatitis is limited 
to a few studies. The treatment led to sustained elimination of HDV RNA in only about 20-25% of 
patients [1,3]. Its efficacy in a real world scenario is not known. The aim of this study was to 
determine the efficacy and safety of PEG-IFN given for 48 weeks for the treatment naïve patients 
with chronic hepatitis D in real-world clinical setting. 
MATERIALS AND METHODS 
Participants: 
All the patients with chronic hepatitis D who were treated with PEG-IFN alpha from 2009 to 2011 
were considered for inclusion in this retrospective analysis. The patients hailed from three centers 
that were following the same algorithm to treat hepatitis D. The liver biopsy and PCR studies 
were done in a single center. Inclusion criteria were the patients of age between 18-60 years with 
chronic hepatitis D and compensated liver disease, HBsAg reactive and anti-HDV antibody 
positive for at least 6 months, presence of HDV RNA in blood by PCR, alanine aminotransferase 
(ALT) levels more than the upper limit of normal (ULN), hemoglobin  10.0 gram/dl, white blood 
cell count of  2.5 x 10
9
 /L, neutrophils  1.5 x 10
9
/L, platelet  75 x 10
9
/L, and negative tests for 
hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Exclusion criteria were the 
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patients who had received antiviral therapy within the previous 6 months, evidence of other 
genetic, autoimmune or metabolic liver diseases, pregnant or breastfeeding women, alcohol 
abuse, uncontrolled psychiatric disease, severe chronic pulmonary, renal or cardiac diseases, 
bleeding disorders, elevated alpha-fetoprotein >100 ng/ml and active or suspected cancer 
elsewhere in the body. Liver biopsy specimens were available only in 39 patients. Grading of 
inflammation and the staging of fibrosis was performed according to the Batt’s and Ludwig’s 
classification [5]. All the patients were managed by the usual standards of care. Local ethics 
committees did not find any objection in publication of the data. 
Treatment: 
All patients eligible for antiviral therapy were treated with PEG-IFN alpha 2a (Pegasys®, F. 
Hoffmann-La Roche Ltd, Basel) 180 g subcutaneously per week or PEG-IFN alpha 2b (Peg- 
Intron®, Schering Plough Corp., Kenilworth, NJ) 1.5 g/kg subcutaneous weekly in a weight-
based dosing regimen. Patients were educated regarding administration of pegylated interferon, 
expected adverse events, schedule for laboratory monitoring, and clinic appointment. 
Outcomes: 
Primary end points were undetectable HDV-RNA levels (virological response) and normal ALT 
(biochemical response) at the end of 24 weeks of post treatment follow-up. Secondary end points 
were the normalization of ALT and HDV RNA-negativity at the end of treatment. 
Viral nucleic acids testing: 
Viral nucleic acids were isolated from patients' serum samples by High Pure Viral Ncleic Acid Kit, 
according to the manufacturer's instructions (Roche Diagnostics, USA). HBV DNA PCR 
qualitative analysis was performed by the Cobas Amplicor HBV Monitor (Roche Diagnostic 
Systems, Basel, Switzerland) with a lower detection limit of 500 copies/ml. For HDV RNA, 
qualitative test was based on the reverse transcription PCR of the target gene. Quantification of 
HDV RNA was done by real time PCR having a lower limit of detection of 500 IU/ml. 
On-treatment evaluation: 
Patients were evaluated as outpatients for safety, tolerance and efficacy every 4 weeks during 
treatment until week 48 and then at 72 weeks during the follow-up period. At each visit complete 
blood count and biochemistry was assessed. HDV RNA was checked at screening, 24 weeks, 
end of treatment (48 weeks) and end of follow-up (24 weeks post treatment). Serum HBV DNA 
was tested at screening, week 48, and end of follow-up. 
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Adverse events: 
Serious adverse events were defined as those that were fatal, life-threatening, required inpatient 
hospitalization or discontinuation of treatment. Non-serious adverse events and laboratory 
abnormalities leading to dose modifications and premature withdrawal from therapy were noted. 
Statistical Analysis: 
Intent-to-treat (ITT) efficacy analysis was conducted on all those subjects who were started on 
treatment (n=104). Patients with missing values were considered as non-responders. Additional 
per protocol analysis was made on the population of patients who completed 48 weeks of 
therapy. Data were expressed as the number of subjects with percentages for nominal variables 
or means with standard deviation for continuous variables. Treatment factors associated with 
HDV RNA negativity at week 72 (24 weeks post-treatment) were assessed. The chi-square test 
and Fisher exact tests were used to compare categorical data. Continuous variables were 
evaluated using t-test or non-parametric test (Mann-Whitney U- test). A two-tailed p value <0.05 
was required for statistical significance. 
RESULTS 
A total of 104 patients were treated and followed up between January 2009 and December 2011. 
These included 69 patients who received PEG-IFN alpha-2a (180 g once weekly) and 35 
patients who received PEG-IFN alpha-2b (1.5 g/kg once weekly). Male patients were 91, mean 
age 30.1 ± 10.0 years (range 15-55). Demographic and baseline clinical characteristics of the 
patients are shown in Table 1. 
Hepatitis Be antigen (HBeAg) was reactive in 29 (27.9%) cases while the HBV DNA was 
detectable in 37 (35.6%); 22 were HBeAg positive. Liver biopsy was available in only in 39 cases. 
Mild inflammation was seen in 1, moderate in 12 and severe in 26 patients. Stage of the disease 
was 1-2 in 30 and 3-4 in 9 patients. Cirrhosis of the liver as evident from histology, ultrasound or 
clinical examination was present in 41 (39.4%) patients. One patient had diabetes and five were 
having arterial hypertension. 
With an intention to treat analysis, clearance of HDV RNA at the end of treatment was 
achieved in 44 patients (42.3%) and normalization of ALT in 38 (35%). Both virological and 
biochemical responses were seen in 23 (22.1%) patients. The efficacy of PEG-IFN was sustained 
in 24 (23.1%) each in terms of virological and biochemical responses and in 13 (12.5%) as a 
combined response at 24 weeks follow-up. This data included 2 patients who had detectable 
HDV RNA at the end of treatment but negative PCR six months post treatment. 
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End of treatment virological response (ETR) and sustained virological response (SVR) at 
week 24 post-treatment was associated with negative HDV RNA at 24 weeks of treatment (p 
values 0.001 and 0.000, risk ratio 2.29 (1.29-4.33) and 7.75 (1.98-47.16), odds ratio 3.92 (1.55-
10.11) and 11.56 (2.38-76.39) respectively (Fig. 1). If the HDV RNA was detectable at 24 weeks, 
positive predictive value (PPV) for a detectable RNA at end of treatment was 0.76 (0.54-0.85) and 
negative predictive value (NPV) 0.56 (0.47-0.63). This PPV further increased to 0.95 (0.85-0.99) 
for a detectable PCR at 6 months post treatment and NPV decreased to 0.36 (0.29-0.39). End of 
treatment biological response i.e. normal ALT at the end of treatment was also a predictor of ETR 
and SVR (p = 0.004 and 0.041, risk ratio 1.90 (1.17-2.96) and 2.05 (0.95-4.45), odds ratio 3.29 
(1.32-8.25) and 2.60 (0.93-7.32) respectively. 
Among 80 patients, who could not achieve SVR, 58 were non responders which included 
7 breakthroughs i.e. negative PCR at 24 weeks and detectable HDV RNA at 48 weeks. Three 
patients had undetectable HDV RNA at 24 weeks but were lost to follow up between 24 to 48 
weeks of treatment and were considered non-responders in the intention to treat analysis. The 
rests of the non responders were ‘null’ responders including 3 out of 4 patients who 
decompensated during treatment. Twenty-two patients had end of treatment virological response 
but relapsed. This figure included two patients were lost to follow up after completion of 
treatment. 
Considering patients who completed 48 weeks of therapy (n=98) after excluding dropouts 
(n=3) and therapy discontinuation due to decompensation (n=3), the end of treatment virological 
response was seen in 45% (44/98) and biochemical response in 39% (38/98). Mean ALT was 
49.2 ± 24.8 in responders and 83.0 ± 60.5 in non-responders (p=0.000). Sustained virological 
response who completed the study according to the protocol and the follow-up (n=96) was 25% 
(24/96), biochemical response 25% (24/96) and a combined response in 13/96 (13.5%). Mean 
ALT in patients with SVR was 51.6 ± 60.3 and in patients without SVR 92.8 ± 75.8 (p=0.028). 
The side effects reported by these patients were usually of PEG-IFN and included 
nausea, weakness, fever, bloating, decreased appetite, body aches, headaches, weight loss. 
These side effects did not require a dose reduction. Significant thrombocytopenia was seen in 6 
patients, which required interruption of therapy for 2 weeks in 2 cases, and dose reduction in the 
rest for 3-4 weeks. One patient received interleukin-11 as well, to increase the platelet count. One 
patient developed significant neutropenia and was given filgrastim. Four patients decompensated; 
3 during the treatment after 24 weeks of therapy and one during the follow-up period. All were 
male and had an age of 32, 40, 40 and 45 years. They were having clinical cirrhosis at the time of 
initiation of treatment but fulfilled the inclusion criteria. The patient who deompensated during the 
follow-up period had sustained virological response, while rest of three were non-responders. 
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DISCUSSION 
So far, interferon alpha, standard or pegylated, is the only treatment option for hepatitis D. In a 
systematic meta-analysis, standard interferon alpha led to the end of treatment virological 
response in 32.6% of the patients compared with 7.8% in the untreated controls [4]. Sustained 
virological response was achieved in 17.4% of patients on interferon compared with 5.2% of 
controls. PEG-IFN is considered superior to conventional interferon. However, a head to head 
comparison of PEG-IFN with standard interferon has not been done. The pilot studies using PEG-
IFN alpha-2b (1.5 g per kilogram of body weight per week) for periods of 48 to 72 weeks 
showed a sustained virological response 6 months after the end of treatment in 17 to 43% of the 
treated patients [6–8]. The results of HIDIT-1 trial showed that treatment with PEG-IFN alpha-2a 
for 48 weeks, with or without adefovir, resulted in sustained HDV RNA clearance in about one 
quarter of patients with HDV infection [9]. All these trials were done in a controlled setting. We 
have gathered here the response in the real world scenario while treating these patients in clinics. 
Our experience is not much different from the published clinical trials. 
The incidence of HDV infection in the West is decreasing but the infection is still very 
much prevalent in our country [10]. Though the prevalence of HBsAg positivity is 2.5%, there are 
certain districts with much higher prevalence. This “hepatitis belt” also has the highest prevalence 
of HDV super infection and represents a serious public health problem [11,12]. So we were able 
to get enough patients to offer treatment and compile this data. 
It has been documented previously that despite low rates of eradication of the virus, 
standard interferon may favorably affect the natural history of the disease in the long run [13]. We 
witnessed normalization of ALT in a significant number of patients treated with pegylated 
interferon even without virological response (Fig. 1). The ultimate goal of treatment should be the 
eradication of HBsAg which is difficult to achieve as none of our patients became HBsAg 
negative. 
We followed up our patients only for 24 weeks post treatment and found a sustained 
response of 23%. From our experience of treating hepatitis C with interferon, the possible factors 
that may influence the outcome of treatment in case of hepatitis D could also be genotype and 
viral load, rapid virological response, stage of fibrosis, duration of disease, previous treatment, 
duration of therapy, compliance and IL28B polymorphism. The genotype of HBV and baseline 
HBsAg level might also be the possible predictors. Apparently, hepatitis D behaves in a different 
way from hepatitis C. We tried to find out factors leading to sustained virological response in our 
patients. The genotype of hepatitis D is 1 [14] and of hepatitis B virus is D [15] in our province so 
these factors could not confound our results. Role of HBsAg titer in predicting response has not 
been established [9]. Presence of absence of cirrhosis, degree of inflammation, and stage of 
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fibrosis did not influence the outcome in our study. Kabaçam G et al also found that response rate 
to pegylated interferon is same in patients with or without advanced liver disease [16]. Studies 
have shown that measuring HDV RNA at 24 weeks of therapy and documenting 2-3 log reduction 
may be of help in predicting response [6–8,17]. As we did not have the baseline viral load 
available in all patients we relied on qualitative PCR which was done in all cases at 24 weeks. 
Negative HDV RNA was a strong predictor of sustained virological response in our study (risk 
ratio7.75 (1.98-47.16) If the HDV RNA was detectable at 24 weeks, positive predictive value 
(PPV) for a detectable RNA at 6 months post treatment was 0.95 (0.85-0.99) and a negative 
predictive value of 0.36 (0.29-0.39). This means that patients who still harbor HDN RNA in their 
blood at 24 weeks of treatment are less likely to have SVR, and at the same time negative PCR 
at 24 weeks does not guarantee an SVR. 
The strength of the study is that it included a reasonable number of patients and the 
sample size is much larger than many previous studies. This study tells us the response rate and 
compliance in the real world scenario which was not worse than the controlled settings. The 
shortcomings of this study were that all the baseline parameters done in controlled trials could not 
be done in all patients including quantitative PCR, genotype, and pre-treatment biopsies. The 
patients were followed up for only 24 weeks after treatment and long term follow-up were not 
available to predict sustained response later on. 
In conclusion, treatment with pegylated interferon for hepatitis D is of limited efficacy. It is 
difficult to expect who would respond to the treatment. A detectable HDV RNA at 24 weeks of 
treatment is a good predictor for a failed sustained virological response. 
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Table 1: Baseline characteristics of the study patients 
Characteristics  
Age-years ± S.D. 
median (range) 
 
30.1±10.0 
30.0 (15-55) 
Male gender 91 (87.5%) 
Body mass index (kg/m
2
) 23.5 ± 5.02 
Palpable liver 28 (26.9%) 
Palpable spleen 30 (28.8%) 
Cirrhosis (clinical / biopsy 
/ultrasound) 
41 (39.4%) 
Hemoglobin (g/dl) 13.5 ± 1.9 
TLC (x 10
6
/L) 6.5 ± 2.6 
Platelets (x 10
9
/L) 186 ± 72 
Bilirubin (mg/dl) 0.94 ± 0.78 
ALT (IU/L) 114 ± 100 
GGT(IU/L) 92 ± 98 
Alkaline phosphatase (IU/L) 152 ± 88 
HBeAg-positive patients (%) 29 (27.9%) 
HBV DNA detected 37 (35.6%) 
ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; HBeAg, hepatitis B e antigen; HBV, 
hepatitis B virus; RNA, ribonucleic acid 
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Table 2: Factors associated with sustained virological response (SVR) six months post treatment 
Factor SVR positive 
(n = 24) 
SVR Negative 
(n = 80) 
p value 
Age (years ± S.D.) 33.7 ± 9.2 30.0 ± 10.2 0.111 
Male gender 22 69 0.728 
Body mass index (kg/m
2
) 23.8 ± 3.8 23.4 ± 5.6 0.759 
Cirrhosis 07 34 0.341 
Platelets (x 10
9
/L) 191 ± 89 184 ± 66 0.719 
Baseline ALT (IU/L) 127 ± 135 110 ± 87 0.458 
Baseline GGT (IU/L) 89 ± 80 94 ± 105 0.901 
HBeAg Reactive 05 24 0.380 
HBV DNA detected 09 28 0.813 
Severe Inflammation 
(Biopsy in 39 patients) 
07 19 1.000 
Advanced fibrosis 
(Biopsy in 39 patients) 
02 07 1.000 
HDV RNA level (x 10
6
 IU/ml) (n 
= 30) 
11.6 ± 15.9 7. ± 14.4 0.464 
Pegylated interferon alpha-2a 
Pegylated interferon alpha-2b 
15 
09 
54 
26 
0.649 
Negative HDV RNA at 24 
weeks 
33 26 0.001 
ALT at 24 weeks 63 ± 40 75 ± 43 0.283 
Normal ALT at 48 weeks 13 25 0.041 
Negative HDV RNA at 48 
weeks 
22 22 0.000 
ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; HBeAg, hepatitis B e antigen; HBV, 
hepatitis B virus; HDV, hepatitis D virus; RNA, ribonucleic acid 
Fig 1: Week 24 HDV RNA (Wk 24 PCR) and normalization of alanine aminotransferase (ALT) at 
the end of treatment (Wk 48 ALT) predicting the end of treatment virological response (ETR) and 
sustained virological response (SVR) 

